February 5, 2018 / 7:25 AM / 8 months ago

BRIEF-Shield Therapeutics Says Top-Line Results From Aegis-Ckd Pivotal Phase III Study Of Feraccru​

Feb 5 (Reuters) - Shield Therapeutics Plc:

* ‍ANNOUNCES TOP-LINE RESULTS FROM ITS AEGIS-CKD PIVOTAL PHASE III STUDY OF FERACCRU​

* ‍PRIMARY EFFICACY ENDPOINT NOT ACHIEVED​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below